News >

Stereotactic Ablative Radiation Slows Progression in Oligometastatic Prostate Cancer

Jason M. Broderick @jasoncology
Published: Friday, Mar 27, 2020

Phuoc Tran, MD, PhD, professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center

Phuoc Tran, MD, PhD

Stereotactic ablative radiation (SABR) reduced disease progression compared with observation in patients with oligometastatic prostate cancer, according to findings from the phase II ORIOLE study published in JAMA Oncology.1,2

Tran and his team are also exploring SABR in the RAVENS trial (NCT04037358), which is combining SABR with radium-223 (Xofigo) in patients with oligometastatic prostate cancer.


  1. Intense Form of Radiation Slows Disease Progression in Some Men with Prostate Cancer That Has Spread. Published online March 26, 2020. Accessed March 27, 2020.
  2. Phillips R, Shi WY; Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial [published online March 26, 2020]. JAMA Oncol. doi:10.1001/jamaoncol.2020.0147

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication